Endometrial Cancer - Pipeline Insight, 2025

This “Endometrial Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Endometrial Cancer: Understanding

Endometrial Cancer: Overview

Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly. The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body. Endometrial cancer is a type of cancer that begins as a growth of cells in the uterus. The uterus is the hollow, pear-shaped pelvic organ where fetal development happens. Endometrial cancer begins in the layer of cells that form the lining of the uterus, called the endometrium. Endometrial cancer is sometimes called uterine cancer.

Symptoms of endometrial cancer may include vaginal bleeding after menopause, bleeding between periods, pelvic pain. The cause of endometrial cancer isn't known. Endometrial cancer starts when cells in the lining of the uterus, called the endometrium, get changes in their DNA. A cell's DNA holds the instructions that tell the cell what to do. The risk factors associated with the endometrial cancer are as follows changes in the balance of hormones in the body, more years of menstruation, never having been pregnant, older age, obesity, hormone therapy for breast cancer and an inherited syndrome that increases the risk of cancer.

The endometrial cancer is diagnosed by using different tests and procedures that include examining the pelvis, imaging tests, and using a scope to examine your endometrium, called a hysteroscopy, removing a sample of tissue for testing, called a biopsy, performing surgery to remove tissue for testing. Endometrial cancer is usually first treated with surgery to remove the cancer. This may include removing the uterus, fallopian tubes and ovaries. Other treatment options may include radiation therapy or treatments using medicines to kill the cancer cells, surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Options for treating endometrial cancer will depend on the characteristics of the cancer, such as the stage, general health and other preferences.  

'Endometrial Cancer - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometrial Cancer pipeline landscape is provided which includes the disease overview and Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Endometrial Cancer.

Endometrial Cancer Emerging Drugs Chapters

This segment of the Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometrial Cancer Emerging Drugs

LENVIMA: Merck & Co

Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.

XMT 1660: Mersana Therapeutics

XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.

VLS-1488: Volastra Therapeutics, Inc.

VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra’s innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.

Endometrial Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endometrial Cancer

• There are approx. 50+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

Phases

The report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometrial Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometrial Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometrial Cancer drugs.

Endometrial Cancer Report Insights

• Endometrial Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Endometrial Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Endometrial Cancer drugs?
• How many Endometrial Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometrial Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endometrial Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endometrial Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co
• ImmunoGen
• Mersana Therapeutics
• Volastra Therapeutics, Inc
• BeiGene/Jazz Pharmaceuticals
• Iconic Therapeutics
• AstraZeneca/Daiichi Sankyo
• Apollomics
• Tempest Therapeutics
• Totus Medicines
• TORL Biotherapeutics
• Tango Therapeutics
• Theratechnologies
• Synthon
• Klus Pharma
• Seagen
• Karyopharm Therapeutics
• Inspirna
• Chimerix

Key Products

• LENVIMA
• Mirvetuximab soravtansine
• XMT 1660
• VLS-1488
• ZW25
• XB002
• Trastuzumab deruxtecan
• TQB2450
• TPST-1495
• TOS-358
• TORL-1-23
• TNG260
• TH1902
• SYD985
• SKB264
• SGN-STNV
• SGNB 7H4V
• Selinexor
• RGX-104
• Dordaviprone

This product will be delivered within 5-7 business days.